Drug news
Afatinib(Boehringer) enters Phase III trials for Head and Neck Cancer
Afatinib from Boehringer enters Phase III trials for Head and Neck cancer.LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate Afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.